94.15
前日終値:
$93.67
開ける:
$93.62
24時間の取引高:
13.74M
Relative Volume:
9.90
時価総額:
$7.12B
収益:
$35.93M
当期純損益:
$-244.56M
株価収益率:
-23.84
EPS:
-3.95
ネットキャッシュフロー:
$-157.31M
1週間 パフォーマンス:
+38.01%
1か月 パフォーマンス:
+43.00%
6か月 パフォーマンス:
+123.69%
1年 パフォーマンス:
+88.45%
Merus N V Stock (MRUS) Company Profile
MRUS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MRUS
Merus N V
|
94.15 | 7.10B | 35.93M | -244.56M | -157.31M | -3.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-17 | 開始されました | Barclays | Overweight |
2025-08-25 | 開始されました | Alliance Global Partners | Buy |
2025-02-13 | 開始されました | Piper Sandler | Overweight |
2025-02-07 | 開始されました | Wells Fargo | Overweight |
2024-11-21 | 開始されました | Goldman | Buy |
2024-10-24 | 開始されました | UBS | Buy |
2024-03-28 | 開始されました | Truist | Buy |
2024-03-04 | 繰り返されました | Needham | Buy |
2023-11-02 | 開始されました | Canaccord Genuity | Buy |
2023-08-21 | 開始されました | TD Cowen | Outperform |
2022-08-02 | 開始されました | Stifel | Buy |
2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
2022-02-10 | 開始されました | Needham | Buy |
2021-11-17 | 再開されました | Guggenheim | Buy |
2021-06-07 | アップグレード | Citigroup | Neutral → Buy |
2021-04-08 | 開始されました | William Blair | Outperform |
2021-03-16 | 開始されました | SVB Leerink | Outperform |
2020-06-26 | 開始されました | H.C. Wainwright | Buy |
2020-05-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-20 | 再開されました | Guggenheim | Buy |
2019-06-28 | 開始されました | ROTH Capital | Buy |
2019-04-12 | 再開されました | Guggenheim | Buy |
2019-04-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2019-03-27 | 開始されました | Berenberg | Buy |
2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-03-21 | ダウングレード | Citigroup | Buy → Neutral |
2016-12-22 | アップグレード | Citigroup | Neutral → Buy |
2016-11-07 | ダウングレード | Citigroup | Buy → Neutral |
2016-06-13 | 開始されました | Citigroup | Buy |
2016-06-13 | 開始されました | Guggenheim | Buy |
2016-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Merus N V (MRUS) 最新ニュース
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V.MRUS - The AI Journal
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS) - PR Newswire
Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab - Latham & Watkins LLP
Genmab Nears Deal to Buy Cancer Drugmaker Merus - MSN
This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
MRUS Analyst Rating Update: Guggenheim Downgrades to Neutral | M - GuruFocus
MRUS Analyst Rating Update: Canaccord Genuity Adjusts PT and Rat - GuruFocus
Merus (MRUS) Sees Rating Downgrade and Target Price Raise by Wells Fargo | MRUS Stock News - GuruFocus
Merus (MRUS) Receives Rating Downgrade by LifeSci Capital | MRUS Stock News - GuruFocus
Barclays Downgrades MRUS, Lowers Price Target Amid Market Adjustments | MRUS Stock News - GuruFocus
Merus (MRUS) Sees Downgrade from UBS with Raised Price Target | MRUS Stock News - GuruFocus
Merus (NASDAQ:MRUS) Receives "Market Perform" Rating from Lifesci Capital - MarketBeat
Barclays Downgrades Merus to Equalweight From Overweight, Adjusts Price Target to $97 From $112 - MarketScreener
BMO Capital Downgrades Merus to Market Perform From Outperform, Adjusts Price Target to $97 From $110 - MarketScreener
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal - Stocktwits
Merus (NASDAQ:MRUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
Genmab Bets Big On Cancer With $8 Billion Merus Deal - Finimize
Merus Reaches Analyst Target Price - Nasdaq
MRUS Stock Downgraded: HC Wainwright & Co. Lowers Price Target | - GuruFocus
Genmab to acquire Merus shares for $8bn - Yahoo Finance
Barclays downgrades Merus stock to Equalweight, cuts price target on valuation - Investing.com
Guggenheim downgrades Merus stock to Neutral following Genmab acquisition - Investing.com
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - AD HOC NEWS
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction - Yahoo Finance
EQT Is Shareholder in Merus, Acquired by Denmark's Genmab - MarketScreener
Merus stock rating downgraded by UBS after Genmab acquisition - Investing.com India
Genmab to acquire Merus for $8 billion in cash deal By Investing.com - Investing.com Australia
What’s the recovery path for long term holders of Merus N.V.Market Volume Report & Smart Money Movement Alerts - newser.com
Genmab to acquire Merus for $8 billion in cash deal - Investing.com
Genmab swallows Merus in US$8bn deal - European Biotechnology Magazine
Genmab adding late-stage bispecific in $8B Merus acquisition - BioWorld MedTech
Mid Cap Stocks To ConsiderSeptember 29th - MarketBeat
Will Merus N.V. stock see PE expansionLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Merus N.V. Stock: Analyzing Recent Fluctuations - timothysykes.com
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes - FinancialContent
Leadership Changes and Bold Moves Shake Global Drugmakers - Devdiscourse
Merus (MRUS) Experiences Surge with Significant Stock Price Incr - GuruFocus
Genmab’s $8B Merus takeout is latest push toward full ownership of programs - biocentury.com
Can Merus Sustain The Leap? - StocksToTrade
Transcript : Genmab A/S, Merus N.V.M&A Call - MarketScreener
MRUS: Truist Securities Downgrades Rating, Raises Price Target | MRUS Stock News - GuruFocus
Promising Medical Stocks To Keep An Eye OnSeptember 29th - MarketBeat
Genmab to Acquire Merus in $8 Billion Biotech Deal - USA Herald
MRUS Shares Surge Amid Acquisition Talks - timothysykes.com
4 Firms Advise On Genmab's $8B Merus Acquisition Plan - Law360
HC Wainwright Downgrades Merus to Neutral From Buy, Price Target at $97 - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus - A&O Shearman
Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters
Genmab Makes $8 Billion Bet On Cancer Drugmaker Merus - Finimize
Merus N V (MRUS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):